Evaluation
*
HighAbove AverageAverageBelow AverageLow
John Marshall, MD
Robin Sommers, NP, DNP, ANP-BC, AONCP
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Restate the current standard of care options for the first-line mCRC therapy, using chemotherapy in combination with targeted agents
Identify which patients should undergo mutation testing, and understand how these results impact selection of therapy
Assess the potential utility of other predictive biomarkers
Update the incorporation of biologics into the management of colorectal cancer
Discuss indications for and potential benefits of radiation therapy in patients with unresectable disease
Compare the potential benefits and limitation of oral cancer therapy for mCRC
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*